RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Henlius, a biosimilar/innovative biologics subsidiary of Fosun Pharma, reported the European Medicines Agency (EMA) has accepted its Marketing Authorization Application of a Herceptin (trastuzumab) biosimilar for review. The company says HLX02 is the first China-developed biosimilar to achieve this milestone, as well as the first China-developed trastuzumab biosimilar accepted in China. The candidate is indicated for HER2+ breast cancer and untreated HER2+ metastatic gastric/gastroesophageal junction (GEJ) cancer. Henlius has out-licensed European rights for HLX02 to Accord Healthcare.
Source: China Biotoday
